Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05414500 · ClinicalTrials.gov registry record · Phase 1
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
A Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05414500: Recruiting Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by University of Alabama at Birmingham.
NCT05414500 is a Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 10 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05414500, a Phase 1 study of Cutaneous T Cell Lymphoma and Mycosis Fungoides, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.
Conditions Studied
Interventions
- DRUG Brentuximab vedotin
- DRUG Mogamulizumab
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
What NCT05414500 shows while recruiting
NCT05414500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Brentuximab vedotin is the first listed.
NCT05414500 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05414500 about?
NCT05414500 is a clinical study titled "Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides". This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future ...
What is the current status of trial NCT05414500?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-05-01. Estimated completion is 2026-07-31.
What conditions does trial NCT05414500 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides.
What interventions are being tested in trial NCT05414500?
The interventions under investigation include: Brentuximab vedotin (DRUG), Mogamulizumab (DRUG).
Who is sponsoring clinical trial NCT05414500?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05414500 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05414500's enrollment target sits among peer trials
10 23rd of 23 the lowest of 23 other Cutaneous T Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous T Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
COMPLETED · Phase 1
-
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI